Study Details | To compare the efficacy of OAV101 IT vs. sham control as measured by the change from baseline in HFMSE total score |
Protocol Number | COAV101B12301 |
Phase | III |
Therapeutic Area | Paediatrics with Type 2 SMA |
Subject Types | With Medical Condition |
Indication | Type 2 SMA |
Principal Investigator | A/Prof Stacey Tay |
Investigator Product / Device | OAV101 |
Sponsor | Novartis (Singapore) Pte Ltd |